Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor

Yi‐Yun Yu(AbbVie (United States)), Michael R. Michaelides(AbbVie (United States)), Thomas D. Penning(Abbott Fund), Jacob V. Gorman(AbbVie (United States)), Robin R. Frey(AbbVie (United States)), Richard F. Clark(UC San Diego Health System), Jin Wang(AbbVie (United States)), Ki Moon Ryu(Dong-A ST (South Korea)), Albert Lai(AbbVie (United States)), Clarissa G. Jakob(AbbVie (United States)), Leiming Li(First Hospital of China Medical University), Nicolas J. Kapecki(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), F. Gregory Buchanan(AbbVie (United States)), Ruth L. Martin(AbbVie (United States)), Matthew D. Kurnick(AbbVie (United States)), Kenneth D. Bromberg(AbbVie (United States)), Jane Gong(AbbVie (United States)), Hadong Kim(Dong-A ST (South Korea)), Anup K. Upadhyay(Emory University), Jin Kwan Kim(Dong-A ST (South Korea)), Julie M. Miyashiro(AbbVie (United States)), Tao Li(AbbVie (United States)), Heath A. Smith(AbbVie (United States)), Ashish Thakur(Agricultural Institute), Wei Qiu(Neijiang Normal University), Tae‐young Yoon(Dong-A ST (South Korea)), Seong Jin Park(Dong-A ST (South Korea)), Yujia Dai(Sichuan Agricultural University), Maricel Torrent(United States Military Academy), Gui‐Dong Zhu(Abbott Fund), Debra Montgomery(AbbVie (United States)), Hyung Ki Lee(Dong-A ST (South Korea)), Vlasios Manaves(AbbVie (United States)), Stella Z. Doktor(AbbVie (United States)), Miyeon Jang(Dong-A ST (South Korea))
Journal of Medicinal Chemistry
September 16, 2024
Cited by 8


Related Papers